{"id":390860,"date":"2017-11-10T00:00:00","date_gmt":"2017-11-10T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfim0004-2017-biopharma-crohns-disease-disease-landscape-and-forecast-g7-2017\/"},"modified":"2026-03-31T10:49:38","modified_gmt":"2026-03-31T10:49:38","slug":"dlsfim0004-2017-biopharma-crohns-disease-disease-landscape-and-forecast-g7-2017","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfim0004-2017-biopharma-crohns-disease-disease-landscape-and-forecast-g7-2017\/","title":{"rendered":"Crohn&#8217;s Disease | Disease Landscape and Forecast | G7 | 2017"},"content":{"rendered":"<p><strong>MARKET OUTLOOK<\/strong><\/p>\n<p>The Crohn\u2019s disease (CD) therapy market will continue to evolve over the next decade. The well-established tumor necrosis factor-alpha (TNF-\u03b1) inhibitors (e.g., Janssen\/Merck\u2019s Remicade, AbbVie\/Eisai\u2019s Humira) helped transform the treatment landscape, especially for patients with moderate to severe disease, despite their efficacy limitations (e.g., patients lose response over time) and safety risks. Takeda\u2019s Entyvio, a cell adhesion molecule (CAM) inhibitor, which launched in 2014, offered an alternative treatment, especially for patients refractory to\u00a0TNF-\u03b1 inhibitors. Most recently, the introduction of the first-in-class interleukin (IL)-12\/23 inhibitor, Janssen\u2019s Stelara, has expanded physicians\u2019 treatment armamentarium and will further intensify market competition. Emerging therapies include more-convenient formulations of current agents and drugs with novel mechanisms of action (MOAs) (e.g., Galapagos\/Gilead\u2019s filgotinib); these products, together with the increasing availability of biosimilar agents, will further complicate the treatment landscape.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<p>What are key opinion leaders\u2019 (KOLs\u2019) insights on current treatment options for\u00a0CD\u00a0(e.g., Remicade, Humira, Inflectra\/Remsima)? What factors drive their treatment decisions?<\/p>\n<p>What has been\/will be the impact of the newer, non-TNF\u00a0biologics (e.g., Janssen\u2019s Stelara, Takeda\u2019s Entyvio) on the\u00a0CD\u00a0treatment algorithm?<\/p>\n<p>What is\u00a0KOLs\u2019 opinion of the emerging oral therapies (e.g., Galapagos\/Gilead\u2019s filgotinib)? What impact will stem-cell therapies (e.g., TiGenix\/Takeda\u2019s Cx-601) have on the\u00a0CDmarket?<\/p>\n<p>How will the market evolve over the next ten years? What impact will biosimilar agents have on the use of their branded counterparts and on the overall therapy market?<\/p>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n","protected":false},"template":"","class_list":["post-390860","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-crohns-disease","biopharma-date-890"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390860","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390860\/revisions"}],"predecessor-version":[{"id":576798,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390860\/revisions\/576798"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390860"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}